Vaxcyte to Report Fourth Quarter and Full Year 2021 Financial Results on February 28, 2022
Vaxcyte, Inc. (PCVX) will report its fourth quarter and full year 2021 financial results on February 28, 2022, after market close. The management will host a conference call at 4:30 p.m. ET to discuss these results and provide a business update. Vaxcyte is focused on developing innovative vaccines, with its lead candidate being VAX-24, a 24-valent pneumococcal conjugate vaccine aimed at preventing invasive pneumococcal disease. The company utilizes advanced synthetic techniques, including the XpressCF™ platform, to enhance vaccine efficacy and production.
- Vaxcyte is developing VAX-24, a 24-valent vaccine targeting invasive pneumococcal disease.
- The company employs innovative synthetic techniques, potentially accelerating vaccine production and enhancing immunological benefits.
- None.
SAN CARLOS, Calif., Feb. 17, 2022 (GLOBE NEWSWIRE) -- Vaxcyte, Inc. (Nasdaq: PCVX), a vaccine innovation company engineering high-fidelity vaccines to protect humankind from the consequences of bacterial diseases, today announced that it will report financial results for the fourth quarter and full year 2021 after market close on February 28, 2022. Company management will host a conference call and webcast beginning at 4:30 p.m. ET / 1:30 p.m. PT that day to discuss the financial results and provide a business update.
To participate in the conference call, please dial (833) 519-1403 (domestic) or (270) 215-9736 (international) and refer to conference ID 6886437. A live audio webcast will be available in the Investors & Media section of the Company’s website at www.vaxcyte.com. A replay of the webcast will be available for 30 days following the call.
About Vaxcyte
Vaxcyte is a vaccine innovation company engineering high-fidelity vaccines to protect humankind from the consequences of bacterial diseases. The Company is developing broad-spectrum conjugate and novel protein vaccines to prevent or treat bacterial infectious diseases. Vaxcyte’s lead candidate, VAX-24, is a 24-valent, broad-spectrum pneumococcal conjugate vaccine being developed for the prevention of invasive pneumococcal disease. Vaxcyte is re-engineering the way highly complex vaccines are made through modern synthetic techniques, including advanced chemistry and the XpressCF™ cell-free protein synthesis platform, exclusively licensed from Sutro Biopharma, Inc. Unlike conventional cell-based approaches, the Company’s system for producing difficult-to-make proteins and antigens is intended to accelerate its ability to efficiently create and deliver high-fidelity vaccines with enhanced immunological benefits. Vaxcyte’s pipeline also includes VAX-XP, a PCV with an expanded breadth of coverage of greater than 30 strains; VAX-A1, a prophylactic vaccine candidate designed to prevent Group A Strep infections; and VAX-PG, a therapeutic vaccine candidate designed to slow or stop the progression of periodontal disease. Vaxcyte is driven to eradicate or treat invasive bacterial infections, which have serious and costly health consequences when left unchecked. For more information, visit www.vaxcyte.com.
Contacts:
Andrew Guggenhime, President and Chief Financial Officer
Vaxcyte, Inc.
650-837-0111
investors@vaxcyte.com
Janet Graesser, Vice President, Corporate Communications and Investor Relations
Vaxcyte, Inc.
917-685-8799
media@vaxcyte.com
FAQ
When will Vaxcyte report its earnings for Q4 and full year 2021?
What is Vaxcyte's lead vaccine candidate?
How can I listen to Vaxcyte's conference call on financial results?
